Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes

Journal of Glaucoma

Volumn 24, Issue 1, 2015, Pages 51-54

  Wang, Rong Fang ^a   Williamson, Jennifer E ^a   Kopczynski, Casey ^b   Serle, Janet B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b and Durham   (United States)

Author keywords

Aqueous humor flow rates; AR 13324; Norepinephrine transporter inhibitor; Outflow facility; Rho kinase inhibitor

Indexed keywords

NETARSUDIL; NORADRENALIN TRANSPORTER; ANTIHYPERTENSIVE AGENT; EYE DROPS; RHO KINASE;

ADULT; ANIMAL EXPERIMENT; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR OUTFLOW; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; AQUEOUS HUMOR; DRUG EFFECTS; OCULOPLETHYSMOGRAPHY; PHYSIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; FEMALE; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OPHTHALMIC SOLUTIONS; RHO-ASSOCIATED KINASES; TONOMETRY, OCULAR;

EID: 84924931005     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3182952213     Document Type: Article

References (47)

1. Waki M, Yoshida Y, Oka T, et al. Reduction of intraocular pressure by topical administration of an inhibitor of the Rhoassociated protein kinase. Curr Eye Res. 2001;22:470-474.
2. Honjo M, Inatani M, Kido N, et al. Effect of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119:1171-1178.
3. Honjo M, Tanihara H, Inatani M, et al. Effects of rhoassociated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
4. Fukunaga T, Ikesugi K, Nishio M, et al. The effect of the Rhoassociated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading. Curr Eye Res. 2009;34:42-47.
5. Nishio M, Fukunaga T, Sugimoto M, et al. The effect of the H- 1152P, a potent Rho-Associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes. Curr Eye Res. 2009;34:282-286.
6. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective Rho-Associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216-3222.
7. Yingling JD, Arnold JJ, deLong MA, et al. IOP-lowering efficacy and tolerability of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. Invest Ophthalmol Vis Sci. 2009;50:E-Abstract 4063.
8. Wang RF, Serle JB, Kopczynski C. Effect of 0.06% AR-12286 on aqueous humor dynamics in normotensive monkey eyes. Invest Ophthalmol Vis Sci. 2011;52:E-Abstract 1465.
9. Henderson AJ, Hadden M, Guo C, et al. 2, 3-diaminopyrazines as Rho kinase inhibitors. Bioorg Med Chem Lett. 2010;20:1137-1140.
10. Davis RL, Kahraman M, Prins TJ, et al. Benzothiophene containing Rho kinase inhibitors: efficacy in an animal model of glaucoma. Bioorg Med Chem Lett. 2010;20:3361-3366.
11. Tian B, Wang RF, Podos SM, et al. Effect of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys. Arch Ophthalmol. 2004;122:1171-1177.
12. Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure lowering effects and safety of topical administration of selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309-315.
13. Williams RD, Novack GD, Van Haarlem T, et al. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834-841.
14. Wiederholt M. Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. Curr Opin Ophthalmol. 1998;9:46-49.
15. Wiederholt M, Groth J, Strauss O. Role of protein tyrosine kinase on regulation of trabecular meshwork and ciliary muscle contractility. Invest Ophthalmol Vis Sci. 1998;39: 1012-1020.
16. Rao PV, Deng PF, Kumar J, et al. Modulation of aqueous humor outflow facility by the Rho kinase specific inhibitor Y- 27632. Invest Ophthalmol Vis Sci. 2001;42:1029-1037.
17. Tian B, Kaufman PL. Effects of the Rho kinase inhibitor Y- 27632 and the phosphates inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res. 2005;80:215-225.
18. Lu Z, Overby DR, Scott PA, et al. The mechanism of increasing outflow facility by rho-kinase inhibition with Y- 27632 in bovine eyes. Exp Eye Res. 2008;86:271-281.
19. Tian B, Millar C, Kaufman PL, et al. Effect of H-7 on the iris and ciliary muscle in monkeys. Arch Ophthalmol. 1998;116:1070-1077.
20. Tian B, Geiger B, Epstein DL, et al. Cytoskeletal involvement in the regulation of aqueous humor flow. Invest Ophthalmol Vis Sci. 2000;41:619-623.
21. Zhang M, Maddala R, Rao PV. Novel molecular insight into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol. 2008;295:C1057-C1070.
22. Mandell KJ, Kudelka MR, Wirostko B. Rho kinase inhibitors for treatment of glaucoma. Expert Rev Ophthalmol. 2011;6: 611-622.
23. Tian B, Kaufman PL. Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medications. Expert Rev Ophthalmol. 2012;7:177-187.
24. Nakajima E, Nakajima T, Minagawa Y, et al. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci. 2005;94:701-708.
25. Sugiyama T, Shibata M, Kajiura S, et al. Effects of fasudil, a Rho-Associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci. 2011;52: 64-69.
26. Tokushige H, Waki M, Takayama Y, et al. Effects of Y-39983, a selective Rho-Associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011;36:964-970.
27. Hirata A, Inatani M, Inomata Y, et al. Y-27632, a Rhoassociated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol. 2008;246:51-59.
28. Tura A, Schuettauf F, Monnier PP, et al. Efficacy of Rhokinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci. 2009;50:452-461.
29. Bertrand J, Di Polo A, McKerracher L. Enhanced survival and regeneration of axotomized retinal neurons by repeated delivery of cell-permeable C3-like Rho antagonists. Neurobiol Dis. 2007;25:65-72.
30. Bertrand J, Winton MJ, Rodriguez-Hernandez N, et al. Application of Rho antagonist to neuronal cell bodies promotes neuritis growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats. J Neurosci. 2005;25:1113-1121.
31. Meyerter Vehn T, Sieprath S, Katzenberger B, et al. Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:4895-4904.
32. Meyer-Ter-Vehn T, Katzenberger B, Han H, et al. Lovastatin inhibits TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2008;49:3955-3960.
33. Honjo M, Tanihara H, Kameda T, et al. Potential role of Rhoassociated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48: 5549-5557.
34. Kopczynski C, Lin C-W, Sturdivant J, et al. IOP-lowering efficacy and tolerability of AR-13324, a dual mechanism kinase inhibitor for treatment of glaucoma. Invest Ophthalmol Vis Sci. 2012;53:E-Abstract 5080.
35. Rao PV, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21:167-177.
36. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res. 2000;19:271-295.
37. Rao PV, Deng P, Sasaki Y, et al. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility. Exp Eye Res. 2005;80: 197-206.
38. Ramachandran C, Patil RV, Combrink K, et al. Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork. Mol Vis. 2011;17:1877-1890.
39. Rao PV, Deng P, Maddala R, et al. Expression of dominant of negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow. Mol Vis. 2005;11:288-297.
40. Sabanay I, Tian B, Gabelt BT, et al. Functional and structural reversibility of H-7 effects on conventional aqueous outflow pathway in monkeys. Exp Eye Res. 2004;78:137-150.
41. Sabanay I, Gabelt BT, Tian B, et al. H-7 effects on the structure and fluid conductance of monkey trabecular meshwork. Arch Ophthalmol. 2000;118:955-962.
42. Koga T, Awai M, Tsutsui J, et al. Rho-Associated protein kinase inhibitor, Y-27632, induces alternations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res. 2006;82:362-370.
43. Serle JB, Steidl S, Wang R-F, et al. Selective a2-Adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys. Arch Ophthalmol. 1991;109:1158-1162.
44. Wang R-F, Lee P-Y, Taniguchi T, et al. Effect of oxymetazoline on aqueous humor dynamics and ocular blood flow in monkeys and rabbits. Arch Ophthalmol. 1993;111:535-538.
45. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
46. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8-14.
47. Schadlu R, Maus TL, Nau CB, et al. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol. 1998;116:1441-1444.